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BRIEF COMMUNICATION

De novo variants of NR4A2 are associated with
neurodevelopmental disorder and epilepsy
Sakshi Singh, PhD1, Aditi Gupta, PhD2,3, Michael Zech, MD4,5, Ashley N. Sigafoos, BS2,6,
Karl J. Clark, PhD2,6, Yasemin Dincer, MS7,8, Matias Wagner, MD4,5, Jennifer B. Humberson, MD9,
Sarah Green, MS10, Koen van Gassen, PhD1, Tracy Brandt, PhD FACMG11,
Rhonda E. Schnur, MD FACMG11, Francisca Millan, MD FACMG11, Yue Si, MD PhD11,
Volker Mall, MD7,12, Juliane Winkelmann, MD4,5,13,14, Ralitza H. Gavrilova, MD2,15,16,
Eric W. Klee, PhD2,3,15, Kendra Engleman, MS17, Nicole P. Safina, MD17, Rachel Slaugh, MS18,
Emily M. Bryant, MS19, Wen-Hann Tan, BMBS20, Jorge Granadillo, MD18, Sunita N. Misra, MD PhD19,
G. Bradley Schaefer, MD10, Shelley Towner, MS9, Eva H. Brilstra, MD PhD1 and
Bobby P. C. Koeleman, PhD 1
Purpose: This study characterizes the clinical and genetic features
of nine unrelated patients with de novo variants in the NR4A2 gene.

in expression of abnormal transcripts likely subject to nonsensemediated decay.

Methods: Variants were identified and de novo origins were
confirmed through trio exome sequencing in all but one patient.
Targeted RNA sequencing was performed for one variant to
confirm its splicing effect. Independent discoveries were shared
through GeneMatcher.

Conclusion: Our study underscores the importance of NR4A2 as a
disease gene for neurodevelopmental disorders and epilepsy. The
identified variants are likely causative of the seizures and additional
developmental phenotypes in these patients.

Results: Missense and loss-of-function variants in NR4A2 were
identified in patients from eight unrelated families. One patient
carried a larger deletion including adjacent genes. The cases
presented with developmental delay, hypotonia (six cases), and
epilepsy (six cases). De novo status was confirmed for eight
patients. One variant was demonstrated to affect splicing and result
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INTRODUCTION
The
NR4A2
gene
encodes
a
steroid–thyroid
hormone–retinoid receptor that acts as a nuclear receptor
(NR) transcription factor. The NR transcription factors
play a regulatory role in various aspects of mammalian
physiology such as neuronal development, inflammation,
carcinogenesis, and memory formation. NR4A2 is required for
development, function, and neurotransmission of dopaminergic neurons.1
The NR4A2 protein consists of two main domains: a DNA
binding domain (DBD) and a ligand binding domain (LBD).

Keywords: NR4A2; epilepsy; seizures; neurodevelopmental disorder; developmental disorder

The DBD is a highly conserved domain containing two C4
type zinc fingers that bind to specific motifs in DNA hormone
response elements, and is connected to the C-terminal LBD
via a linker region. The NR4A2 protein functions by binding
small molecule ligands within conserved ligand binding
patches located in the hydrophobic core of the LBD.2 Ligand
binding induces a conformational change in the LBD leading
to changes in interaction of nuclear receptor coregulators and
other proteins. This alters chromatin structure and gene
expression and, therefore, up and down regulation of target
genes. A mutated gene may encode for a misfolded protein,

1
Department of Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands; 2Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA; 3Department of
Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 4Institut für Neurogenomik, Helmholtz Zentrum München, Munich, Germany; 5Institut für Humangenetik, Klinikum
rechts der Isar, Technische Universität München, Munich, Germany; 6Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA; 7Lehrstuhl für
Sozialpädiatrie, Technische Universität München, Munich, Germany; 8Zentrum für Humangenetik und Laboratoriumsdiagnostik (MVZ), Martinsried, Germany; 9Department of
Pediatrics, University of Virginia, Charlottesville, VA, USA; 10Section of Genetics and Metabolism, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 11GeneDx,
Gaithersburg, MD, USA; 12kbo-Kinderzentrum München, Munich, Germany; 13Lehrstuhl für Neurogenetik, Technische Universität München, Munich, Germany; 14Munich Cluster
for Systems Neurology, SyNergy, Munich, Germany; 15Departments of Clinical Genomics and Neurology, Mayo Clinic, Rochester, MN, USA; 16Department of Neurology, Mayo
Clinic, Rochester, MN, USA; 17Division of Clinical Genetics, Children’s Mercy Kansas City, University of Missouri Kansas City School of Medicine, Kansas city, MO, USA;
18
Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA; 19Ann & Robert H. Lurie Children’s
Hospital, Epilepsy Center, Chicago, IL, USA; 20Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA,
USA. Correspondence: Bobby P. C. Koeleman (b.p.c.koeleman@umcutrecht.nl)

Submitted 4 December 2019; revised 16 April 2020; accepted: 17 April 2020
Published online: 5 May 2020
GENETICS in MEDICINE | Volume 22 | Number 8 | August 2020

1413

BRIEF COMMUNICATION

1234567890():,;

dysfunctional ligand binding pocket, or dysfunctional DNA
binding.
Haploinsufficiency of the NR4A2 gene caused by heterozygous chromosomal deletions was previously associated with
a neurodevelopmental disorder with high penetrance, suggesting that heterozygous loss of NR4A2 is autosomal
dominant.3 NR4A2 knockout in midbrain dopaminergic
neurons of adult mice has shown to result in neuronal
degeneration and impaired motor function.1 Various polymorphisms in NR4A2 have been associated with disorders
related to dopaminergic dysfunction such as Parkinson
disease, schizophrenia, manic depression, and autism spectrum disorder.4–6 To our knowledge, there is only one
previous report of a variant of NR4A2 (NM_006186.3:
c.327dup, p.S110Vfs*2) associated with epilepsy.7
Here we report nine patients with variants in NR4A2 and
developmental delay/intellectual disability with or without
epilepsy.

MATERIALS AND METHODS
Informed consent for genetic testing was obtained from all
patients and parents included in the present study. The
consent and protocols were approved by the respective
institutional ethical review boards (University Medical Centre
Utrecht, Mayo Clinic, Children’s Mercy Kansas City,
Technical University of Munich, University of Arkansas for
Medical Sciences, University of Virginia, Washington University School of Medicine, Boston Children’s Hospital, Ann
& Robert H. Lurie Children’s Hospital). All patients underwent exome sequencing; however, the variant identified in
patient 2 was detected using a targeted exome analysis for
neurodevelopmental genes. The deletion observed in patient 9
was detected by comparative genome hybridization using an
Agilent 180K oligoarray. The microdeletion was verified by
fluorescence in situ hybridization (FISH). All other cases were
analyzed using the complete exome (Supplementary information). By sharing through GeneMatcher,8 we discovered other
patients harboring variants in the NR4A2 gene (patients 2, 4,
5, 7). For these patients, exome sequencing was performed at
GeneDx (Gaithersburg, MD, USA) using the Clinical
Research Exome kit (Agilent Technologies, Santa Clara, CA)
or the IDT xGen Exome Research Panel v1.0. The general
assertion criteria for variant classification are publicly
available on the GeneDx ClinVar submission page (http://
www.ncbi.nlm.nih.gov/clinvar/submitters/26957/). All variants identified in patients tested at GeneDx were reported
as variants of uncertain significance in accordance with
American College of Medical Genetics and Genomics
(ACMG) criteria.9
Variants were annotated based on NR4A2 transcript
NM_006186.3. De novo status of the variant was confirmed
by exome sequencing or Sanger sequencing of parental
samples. In silico tools MaxEntScan, NNSPLICE, and Human
Splicing Factor predicted altered splicing and potential loss of
function (LoF). Targeted RNA sequencing was done using
blood-derived RNA of patient 2 to examine the functional
1414
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consequences of the variant on splicing. Altered splicing was
confirmed by reverse transcription polymerase chain reaction
(RT-PCR) (details are in Supplementary Information Figures S1 and S2). Plot Protein and RStudio v1.1.463 were used
to visualize the variants in Fig. 1. Predicted domain
architecture information for the corresponding amino acids
in the protein was retrieved from databases SMART, Prosite,
InterPro, and Pfam.

RESULTS
We report a case series of nine patients with novel variants
in NR4A2, including eight patients with a confirmed de
novo variant, and one patient with a larger deletion
encompassing NR4A2. The patients (five females, four
males; mean age 12.4 years, age range 2–43 years, at the
time of inclusion in current study) show heterogeneous
phenotypes (detailed phenotypes are given in online
Supplementary information). Their neurodevelopmental
phenotypes are characterized by delayed psychomotor
development (9/9), which was initially normal in two
patients. Individuals presented with varying levels (mild to
severe) of intellectual disability (ID)/developmental delay
(DD). Other features include epilepsy (6/9), speech/
language impairment (5/9), behavioral problems (5/9),
and movement disorder/hypotonia (8/9). Patients presented
with variable epilepsy phenotype, including rolandic
epilepsy, generalized encephalopathy, West syndrome, and
infantile spasms. One patient showed epileptoform activity
and photosensitivity on electroencephalogram (EEG).
Seizure type included tonic clonic, generalized, absence,
and focal seizures. Seizures remained refractory in two
patients and the remaining four became seizure-free on
appropriate antiepileptic drugs. Behavioral problems
included autism, attention deficit–hyperactivity disorder,
hyperactivity, anxiety, and hyposensitivity. Two patients
had ataxia. There was no apparent genotype–phenotype
correlation.
Genetic results

We identified eight patients with intragenic NR4A2 variants
and one patients carrying a larger deletion including NR4A2.
Variants were not present in ExAC and gnomAD. De novo
occurrence of the variants was confirmed for eight of these
patients. The origin of the variant in patient 5 could not be
confirmed due to unavailability of the father, but it was not
maternal. Five patients had missense variants, one had a
microdeletion, and three had nonsense or frameshift variants
leading to a premature stop codon (Table 1, Fig. 1). Four
missense variants and one splice-acceptor site variant
(c.839G>A, p.C280Y; c.914G>A, p.C305Y; c.857T>C, p.
F286S; c.968G>T, p.C323F; c.865-1_865delGCinsAAAAAGGAGT) were located in the DBD of the protein that may
affect DNA binding of the transcription factor. Patient 4
carried a missense variant (c.1175A>G, p.D392G) affecting a
hinge region without any secondary structure in the LBD.
Patient 5 had a nonsense variant (c.1576G>T, p.E526*) in the
Volume 22 | Number 8 | August 2020
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Fig. 1 Schematic view of the distribution of pathogenic variants in NR4A2. (a) Transcript description and locations (marked by circles) of the variants
found in NR4A2 gene. (b) Predicted effects (blue dots) of the pathogenic variants on NR4A2 protein sequence. The c.327dup,p.S110Vfs*2 variant was
published previously.7.

LBD, introducing premature termination. All missense
variants were located in a gene region that is enriched for
pathogenic variants across the NR4A2 gene family (see
Supplementary Figure S4).
Patient 6 had a frameshift variant (c.325dup) in N-terminal
regulatory domain introducing premature termination that is
predicted to lead to nonsense-mediated decay (NMD) and
LoF, similar to the previously published epilepsy patient
(c.327dup).7 Patient 9 carried a chromosomal microdeletion
arr[GRCh37]2q23.3q24.1(154790212_158488241)x1 of size
>3.6 Mb (3698029 bp) encompassing the NR4A2 gene. The
deletion also covered ten flanking genes (KCNJ3, GPD2,
GALNT5, ERMN, CYTIP, ACVR1C, ACVR1, UPP2,
CCDC148, and PKP4).
Various in silico tools predicted that the variant in patient 2
affects splicing that would lead to LoF. This was confirmed by
RT-PCR (see Supplementary Figure S2), which revealed
altered splicing leading to aberrant transcripts with an out
of frame skipping of exon 4 (130 nucleotides), which will
potentially cause truncation and LoF through NMD.
All variants had high predictive scores for a detrimental
effect as predicted by SIFT, PolyPhen-2, and CADD scores.
The NR4A2 gene appears to be under a high selective strain
and extremely intolerant to LoF variation as evidenced from
its high probability of being LoF intolerant (pLI) score (1.0)
and lower than expected missense variant counts (Z-score =
2.24), as observed in both ExAC and gnomAD. The
haploinsufficiency score (HI score = 1.28%) shows this gene
to be highly dosage sensitive. Therefore, intolerance to LoF
can play an important role in the development of pathogenic
phenotypes in patients.3,10,11
GENETICS in MEDICINE | Volume 22 | Number 8 | August 2020

DISCUSSION
We report nine patients with early onset epilepsy and/or a
developmental disorder, of whom eight carried intragenic
variants and on a larger deletion including NR4A2. Six of
these patients with de novo NR4A2 variants had epilepsy. The
apparent intolerance to LoF and missense variation of NR4A2
suggests that these variants are causing the phenotype in
patients.3,10,11 In previous studies, haploinsufficiency of
NR4A2 has been implicated in a neurodevelopmental
phenotype, including significant language impairment11,12
and ID.3,7 These symptoms overlap with those observed in the
patients studied here. We also observed language
impairment in five of nine patients, which may be linked to
the more prominent expression of NR4A2 in the superior
temporal gyrus (STG), a brain region linked to language
development.13
Regardless of the similarities among these nine patients, the
underlying explanations for the phenotypes of patient 4 and
patient 9 may be different. Patient 4 had a deceased sibling
with similar phenotype. Therefore, the de novo variant
detected in patient 4 may not explain the full phenotype,
and another cause, as well as germline mosaicism, should be
considered. For patient 9 the microdeletion also affected ten
other genes that could have contributed to the clinical
features. For example, KCNJ3, also deleted in this patient,
encodes for subunit G-protein activated inward rectifier
potassium channel 1. Alterations in the function of this
potassium channel subunit have been associated with
epilepsy.14
It remains unclear how these variants of NR4A2 contribute
to the epileptogenesis. However, the physiologic role of
1415
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Table 1 Clinical phenotypes of patients with heterozygous de novo and putative de novo NR4A2 variants.
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NR4A2 provides a clue toward the complex phenotypes of the
patients with variants in this gene. NR4A2 is a known
transcription factor and it binds to DNA as monomer or
homodimer to promote constitutive activation of transcription.15 It exerts concentration-dependent effects on target
genes mediating distinct biological processes.16 The product
of a mutated gene can be subjected to NMD leading to a
misfolded protein, or a dysfunctional ligand binding pocket,
or a dysfunctional DNA binding, resulting in impaired or loss
of function. It is important to take into consideration that
amino acid substitutions can also disrupt the conformation of
the protein and such conformational changes might also
compromise the function of NR4A2. A large case–control
study of patients with neurodevelopmental disorders (such as
autism spectrum disorder, DD, ID, and epilepsy) showed
significant clustering of the de novo missense variants in cases
at the protein level for 200 genes including NR4A2. In many
cases, these de novo variants clustered in protein functional
domains (such as zinc finger motifs, transmembrane
domains, voltage sensors, and channel pores) relevant in the
neurodevelopmental pathology. The de novo variants in zinc
finger motifs were not present in public control databases. A
clustering of variants in specific functional domains emphasized the importance of these de novo variants in characterizing pathogenic genes and functional domains.17 The DBD
of NR4A2 contains two highly conserved C4 type zinc
fingers that bind to specific motifs in DNA hormone
response elements. Two of six patients with epilepsy have a
missense variant in the DBD, whereas one patient has a
missense variant in a hinge region with no secondary
structure in the LBD and in N-terminal regulatory region of
the protein. The two missense variants in the highly
conserved DBD of NR4A2 may have resulted in impaired
DNA binding ability. The other variants observed in patients
are truncating variants and deletions, which taken together
with the observed clustering of missense variants in a
biological relevant protein domain strongly suggest that LoF
is the underlying disease mechanism.
It is well established that NR4A2 is important for
differentiation, survival and maintenance of dopaminergic
neurons.1 Furthermore, the dopamine activity transporter
DAT gene has been associated with idiopathic absence
epilepsy and seizures.18 Various animal studies have investigated how the DAergic system is linked to epileptogenesis and
neurodevelopmental dysfunction.1 Different subtypes of the
dopamine receptors can act either as proconvulsant (D1-like
receptor) or anticonvulsant (D2-like receptor). Physiological
balance of DAergic activity at D1R and D2R can be decisive
for complex neuromodulatory response for epileptogenesis.16
The knockout or knockdown of NR4A2 have resulted in poor
motor function and lower number of DA neurons, lower
levels of protein, and reduced DA at birth in midbrain.19
Studies of NR4A2 heterozygosity in animal models have
shown that the affected dopaminergic system is associated
with altered locomotor behavior.20 Furthermore, a crucial role
of NR4A2 in overall survival was supported by animal studies
Volume 22 | Number 8 | August 2020
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revealing its involvement in respiratory abnormality and lack
of response to hypoxia. NR4A2 is encoded by immediate early
genes and has a significant role in development, neuroprotection, learning, and memory formation,19 presenting a reasonable explanation for the associated ID among these patients.
These studies indicate that variants in NR4A2 can impair its
various functions, and plausibly contribute to the seizure,
neurodevelopmental, and global developmental phenotype
observed in the described patients.
SUPPLEMENTARY INFORMATION
The online version of this article (https://doi.org/10.1038/s41436020-0815-4) contains supplementary material, which is available
to authorized users.
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